The provider of specialty ingredients and formulation solutions for the pharmaceutical and personal care industries has validated the production of eight ingredients at its Lufkin, Texas facility.
In concrete terms, three pharmaceutical excipients and five cosmetic ingredients [1] have achieved manufacturing equivalency, marking a key milestone in the company’s strategy to expand regional manufacturing while ensuring consistent quality and reliable supply worldwide.
Officially inaugurated in September 2025, Gattefossé’s first manufacturing unit in North America has already achieved the EXCiPACT® certification (GMP) for pharmaceutical products and EFfCI certification for personal care products.
Each validation is supported by a complete technical equivalence file, including analytical validation, stability data, and regulatory documentation to ensure seamless integration into customers’ development and commercialization programs.
"The validation of our first ingredients at our Lufkin facility is a major achievement for our portfolio. Together, these eight excipients provide formulators with reliable solutions to address today’s formulation challenges. By localizing the production of critical lipid-based excipients, we are directly answering our partners’ need for supply chain resilience and dependable domestic sourcing in an increasingly unpredictable global market," explains Ben Blinder, Chief Operating Officer at Gattefossé USA.
By establishing large-scale oleochemical manufacturing in the United States, Gattefossé intends to expand its capabilities while helping its customers navigate current supply chain challenges.
The Lufkin site is supported by Gattefossé’s global network of Technical Centers of Excellence, located in the United States (Paramus, New Jersey), France, India, and China.
